Arikayce

Treatment of MAC Lung Disease

Arikayce is specifically used to treat lung infections caused by a group of bacteria known as Mycobacterium avium complex (MAC). This condition is a serious, chronic lung disease that can cause symptoms like persistent coughing, fatigue, and shortness of breath.

When It Is Prescribed

This medication is typically reserved for adults who meet the following criteria:

• They have been diagnosed with MAC lung disease.
• They have already tried conventional antibiotic treatments for at least six months, but the infection has not cleared.
• They have limited or no other treatment options available.

Arikayce is not used as a standalone therapy. It is prescribed as part of a combination antibacterial drug regimen to help clear the infection from the lungs. The medication is delivered directly to the lungs using a specific nebulizer system, which allows the antibiotic to reach the site of the infection more effectively.

How Arikayce Fights Infection

Arikayce contains amikacin, an aminoglycoside antibiotic. It works by entering bacterial cells and binding to their ribosomes, which are the structures responsible for making proteins. When the medication binds to these ribosomes, the bacteria can no longer produce the essential proteins they need to grow, multiply, and maintain their structure. This disruption eventually leads to the death of the bacteria.

Liposomal Technology

The medication is unique because the amikacin is encapsulated in liposomes, which are microscopic spheres made of fat-like substances. This liposomal delivery system is designed to help the drug reach the lungs directly when inhaled. Once in the lungs, the liposomes are taken up by immune cells called macrophages, which are the same cells where the bacteria often live. This allows the medication to target the infection more effectively.

Biofilm Penetration

Certain bacteria, such as Mycobacterium avium complex (MAC), can create a protective layer called a biofilm. This layer often makes it difficult for standard antibiotics to reach the bacteria. The liposomal structure of Arikayce is intended to help the antibiotic penetrate these biofilms and reach the bacteria hidden within the lung tissue.

Common Side Effects

Many people using this medication experience respiratory or systemic symptoms. Common side effects may include:

• Coughing or throat irritation
• Hoarseness or voice changes
• Tiredness or fatigue
• Muscle pain
• Headache
• Nausea or diarrhea
• Weight loss
• Fever

Serious Side Effects

Some side effects can be severe and require immediate medical attention. Contact a healthcare provider if you experience:

• Hearing loss or ringing in the ears (tinnitus)
• Dizziness or problems with balance
• Changes in urination or other signs of kidney problems
• Severe shortness of breath or wheezing
• Chest pain or discomfort
• Allergic reactions, such as rash or swelling

Respiratory Risks

Arikayce carries a boxed warning regarding serious lung-related side effects. These conditions may include:

• Hypersensitivity pneumonitis: Allergic inflammation of the lungs that may cause fever, cough, or shortness of breath.
• Hemoptysis: Coughing up blood.
• Bronchospasm: Sudden narrowing of the airways making it difficult to breathe.
• COPD exacerbations: Worsening of symptoms in people with chronic obstructive pulmonary disease.

Hearing and Balance Loss

This medication can cause permanent hearing loss, ringing in the ears (tinnitus), and balance problems such as dizziness or vertigo. Healthcare providers typically monitor hearing through regular testing throughout the course of treatment.

Kidney Damage

Amikacin, the active ingredient in this medication, is known to cause kidney toxicity. Regular blood tests are often used to monitor kidney function. The risk may be higher for individuals with pre-existing kidney issues or those taking other medications that affect the kidneys.

Neuromuscular Weakness

The medication may worsen muscle weakness in people with neuromuscular disorders, such as myasthenia gravis. Caution is advised for patients with these conditions.

Pregnancy Considerations

Aminoglycosides can cause fetal harm, including permanent hearing loss in the newborn, when used during pregnancy. It is important to discuss potential risks with a healthcare provider if pregnancy is possible.

Pregnancy

Arikayce belongs to a class of antibiotics known as aminoglycosides. These medications have the potential to cause harm to a developing fetus. Specifically, aminoglycosides can cross the placenta and may cause permanent, irreversible hearing loss in the unborn baby. While there are no adequate studies on the use of Arikayce specifically in pregnant women, the known risks associated with this class of drugs suggest that it should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Breastfeeding

It is not known whether Arikayce passes into human breast milk, how it affects milk production, or if it has any effects on a breastfed infant. Because of the potential for serious side effects in a nursing child, a decision should be made in consultation with a healthcare provider to either discontinue breastfeeding or discontinue the medication. This decision should take into account the importance of the drug to the mother's health.

Consulting Your Doctor

If you are pregnant, planning to become pregnant, or are breastfeeding, it is important to discuss your situation with a healthcare professional. They can provide guidance on the risks and benefits of continuing treatment with Arikayce during these times.

Available Forms

Arikayce is supplied as a sterile, liposomal inhalation suspension. This medication consists of the active ingredient contained within tiny particles called liposomes, which are suspended in a liquid.

The suspension is provided in vials. It is designed to be used only with the Lamira Nebulizer System. It should not be used with other nebulizers, and it is not intended for injection or oral consumption.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Arikayce in 2018 for the treatment of Mycobacterium avium complex (MAC) lung disease. It is intended for use in adults as part of a combination antibacterial regimen when limited or no other treatment options are available. It was the first medication approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway), which is designed for drugs that address unmet medical needs in specific patient groups.

Accelerated Approval Status

Arikayce was granted accelerated approval based on its ability to achieve sputum culture conversion, which means the bacteria are no longer detected in the patient's mucus. As part of this pathway, the FDA may require further clinical studies to confirm the drug's long-term clinical benefits, such as improvements in symptoms or lung function.

Boxed Warning

The FDA has issued a Boxed Warning for Arikayce due to the risk of serious respiratory adverse reactions. These complications can include:

• Hypersensitivity pneumonitis (inflammation of the lungs).
• Bronchospasm (tightening of the muscles in the airways).
• Worsening of underlying lung disease.
• Hemoptysis (coughing up blood).

Due to these risks, healthcare providers typically monitor patients closely for new or worsening respiratory symptoms during treatment.

Insurance and Pharmacy Access

Arikayce is classified as a specialty medication. It is typically not stocked at local retail pharmacies and must be obtained through a specialty pharmacy. Most insurance plans, including Medicare and private insurance, provide coverage for the drug, but the specific out-of-pocket cost depends on the individual's plan benefits, such as copayments or coinsurance requirements.

Financial Assistance

The manufacturer offers a support program designed to help patients access the medication. This program may include:

• Copay Assistance: Eligible patients with commercial insurance may qualify for copay cards to lower their monthly costs.
• Insurance Navigation: Support staff can help clarify insurance coverage and assist with the prior authorization process.
• Patient Assistance Programs: There may be programs available to provide the medication at no cost or a reduced cost for patients who meet specific financial eligibility criteria and lack adequate insurance coverage.

Patients are encouraged to contact their insurance provider or the specialty pharmacy to determine their specific coverage details and explore available financial aid options.